The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Joseph A. Fraietta, Simon F. Lacey, Elena J. Orlando et al. · Nature Medicine · 2018 · 1.7K citations · Full text

T Cell Therapy, Cancer Immunosurveillance, Chronic Lymphocytic Leukemia +6

Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma

Chrystal U. Louis, Barbara Savoldo, Gianpietro Dotti et al. · Blood · 2011 · 1.1K citations · Full text

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

Leonid Cherkassky, Aurore Morello, Jonathan Villena‐Vargas et al. · Journal of Clinical Investigation · 2016 · 1K citations · Full text

A2A adenosine receptor protects tumors from antitumor T cells

Akio Ohta, Elieser Gorelik, Simon J. Prasad et al. · Proceedings of the National Academy of Sciences · 2006 · 1K citations · Full text

Cancer Immunosurveillance, Medicine, Tumor Growth +12

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

Zeguo Zhao, Maud Condomines, Sjoukje J. C. van der Stegen et al. · Cancer Cell · 2015 · 819 citations · Full text

Car T Cells, Cell Therapy, Cancer Immunosurveillance +13